Fabry Disease Treatment Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Fabry Disease Treatment Market, By Treatment

7.1.  Fabry Disease Treatment Market, By Treatment, 2020-2028

7.1.1.    Enzyme Replacement Therapy (ERT)

7.1.1.1.        Market Revenue and Forecast (2016-2028)

7.1.2.    Chaperone Treatment

7.1.2.1.        Market Revenue and Forecast (2016-2028)

7.1.3.    Substrate Reduction Therapy (SRT)

7.1.3.1.        Market Revenue and Forecast (2016-2028)

7.1.4.    Others

7.1.4.1.        Market Revenue and Forecast (2016-2028)

Chapter 8.  Global Fabry Disease Treatment Market, Regional Estimates and Trend Forecast

8.1.  North America

8.1.1.    Market Revenue and Forecast, By Treatment (2016-2028)

8.1.2.    U.S.

8.1.3.    Rest of North America

8.1.3.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.2.  Europe

8.2.1.    Market Revenue and Forecast, By Treatment (2016-2028)

8.2.2.    UK

8.2.2.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.2.3.    France

8.2.3.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.2.4.    Rest of Europe

8.2.4.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.3.  APAC

8.3.1.    Market Revenue and Forecast, By Treatment (2016-2028)

8.3.2.    India

8.3.2.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.3.3.    China

8.3.3.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.3.4.    Japan

8.3.4.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.3.5.    Rest of APAC

8.3.5.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.4.  MEA

8.4.1.    Market Revenue and Forecast, By Treatment (2016-2028)

8.4.2.    GCC

8.4.2.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.4.3.    North Africa

8.4.3.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.4.4.    South Africa

8.4.4.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.4.5.    Rest of MEA

8.4.5.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.5.  Latin America

8.5.1.    Market Revenue and Forecast, By Treatment (2016-2028)

8.5.2.    Brazil

8.5.2.1.        Market Revenue and Forecast, By Treatment (2016-2028)

8.5.3.    Rest of LATAM

8.5.3.1.        Market Revenue and Forecast, By Treatment (2016-2028)

Chapter 9.    Company Profiles

9.1.  Sanofi S.A.; Shire Plc.

9.1.1.    Company Overview

9.1.2.    Product Offerings

9.1.3.    Financial Performance

9.1.4.    Recent Initiatives

9.2.  Amicus Therapeutics Inc.

9.2.1.    Company Overview

9.2.2.    Product Offerings

9.2.3.    Financial Performance

9.2.4.    Recent Initiatives

9.3.  ISU Abxis Co Ltd.

9.3.1.    Company Overview

9.3.2.    Product Offerings

9.3.3.    Financial Performance

9.3.4.    Recent Initiatives

9.4.  JCR Pharmaceuticals Co Ltd.

9.4.1.    Company Overview

9.4.2.    Product Offerings

9.4.3.    Financial Performance

9.4.4.    Recent Initiatives

9.5.  Protalix Biotherapeutics Inc.

9.5.1.    Company Overview

9.5.2.    Product Offerings

9.5.3.    Financial Performance

9.5.4.    Recent Initiatives

9.6.  Idorsia Pharmaceuticals Ltd.

9.6.1.    Company Overview

9.6.2.    Product Offerings

9.6.3.    Financial Performance

9.6.4.    Recent Initiatives

9.7.  Avrobio Inc.

9.7.1.    Company Overview

9.7.2.    Product Offerings

9.7.3.    Financial Performance

9.7.4.    Recent Initiatives

9.8.  Greenovation Biotech GmbH

9.8.1.    Company Overview

9.8.2.    Product Offerings

9.8.3.    Financial Performance

9.8.4.    Recent Initiatives

9.9.  Moderna Therapeutics Inc.

9.9.1.    Company Overview

9.9.2.    Product Offerings

9.9.3.    Financial Performance

9.9.4.    Recent Initiatives

9.10.              Green Cross Pharma Pte Ltd.

9.10.1.  Company Overview

9.10.2.  Product Offerings

9.10.3.  Financial Performance

9.10.4.  Recent Initiatives

Chapter 10.  Research Methodology

10.1.              Primary Research

10.2.              Secondary Research

10.3.              Assumptions

Chapter 11.  Appendix

11.1.              About Us

Glossary of Terms